HomeFile

File

View Category
Structural heart disease

BASILICA: a Complex Strategy, Yet Safe

Coronary artery obstruction (CAO) after TAVR is rare, but it entails extremely high mortality (50% or more),...
solaci -
Learn More
Structural heart disease

Evolute Low Risk at 3 Years: Promising Outcomes

Transcatheter aortic valve replacement has shown important benefits but one of its biggest challenges is showing its...
solaci -
Learn More
Peripheral vascular disease

CLOUT Registry: Thrombectomy in TVP with ClotTriever

Safety and efficacy of the ClotTriever device in extended deep vein thrombosis.  The endovascular treatment of thromboembolic disease...
solaci -
Learn More
Coronary disease

PICCOLETO-II: Drug-Coated Balloons in Small Vessels

Use of drug-coated balloons vs. drug-eluting stents in small caliber vessels. The constant advancements in coronary device technology...
solaci -
Learn More
Femoropopliteal

Retrograde Tibial Access for Endovascular Treatment of Femoropopliteal Occlusions: Is it a Safe Strategy?

Endovascular recanalization of femoropopliteal occlusions continues to be one of the initial therapeutic strategies to treat this...
solaci -
Learn More
Structural heart disease

Sex-Related Differences in Clinical Outcomes after Transcatheter Tricuspid Valve Intervention

We are aware of sex related differences when it comes to comorbidities, physiopathology and disease evolution in...
solaci -
Learn More
Acute coronary syndromes

Differences in Events Between MINOCA and MIOCA Patients: Contemporaneous Cohort Analysis

Sex-related MINOCA and MIOCA differences. Several international guidelines recommend invasive treatment after diagnosing an acute coronary syndrome (ACS)....
solaci -
Learn More
Coronary disease

Comparative Study of Two Drug Coated Balloons: Angiographic and Clinical Outcomes

The incidence of in-stent restenosis (ISR) requiring repeat revascularization ranges between 5% and 10% of PCI patients...
solaci -
Learn More